Currently, there are no licensed treatments by regulatory authorities for patients with AAE-C1-INH due to the small number of diagnosed patients and lack of clinical trials; therefore, treatment follows the therapy for HAE in an off-label fashion. This evidence concerns the gene SERPING1 and acquired angioedema.